Charles Schwab Investment Management Inc Crinetics Pharmaceuticals, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 759,126 shares of CRNX stock, worth $25.5 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
759,126
Previous 655,418
15.82%
Holding current value
$25.5 Million
Previous $33.5 Million
15.94%
% of portfolio
0.01%
Previous 0.01%
Shares
26 transactions
Others Institutions Holding CRNX
# of Institutions
256Shares Held
82.6MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$305 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$209 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$206 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$182 Million0.03% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA4.29MShares$144 Million10.24% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.8B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...